DK1613304T3 - DPP-IV-inhibitorer - Google Patents

DPP-IV-inhibitorer

Info

Publication number: DK1613304T3
Authority: DK; Denmark
Prior art keywords: dpp; inhibitors; compounds; relates; medicament
Prior art date: 2003-12-09

Application number

DK04803694T

Other languages

English (en)

Inventor

Victor Giulio Matassa

Paul John Edwards

Meritxell Lopez-Canet

Achim Feurer

Silvia Cerezo-Galvez

Sonja Nordhoff

Meinolf Thiemann

Oliver Hill

Original Assignee

Santhera Pharmaceuticals Ch

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-09

Filing date

2004-12-09

Publication date

2008-01-21

2004-12-09 Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch

2008-01-21 Application granted granted Critical

2008-01-21 Publication of DK1613304T3 publication Critical patent/DK1613304T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)

DK04803694T 2003-12-09 2004-12-09 DPP-IV-inhibitorer DK1613304T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03028211A EP1541143A1 (en)	2003-12-09	2003-12-09	Dpp-iv inhibitors
PCT/EP2004/014040 WO2005056003A1 (en)	2003-12-09	2004-12-09	Dpp-iv inhibitors

Publications (1)

Publication Number	Publication Date
DK1613304T3 true DK1613304T3 (da)	2008-01-21

Family

ID=34486147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04803694T DK1613304T3 (da)	2003-12-09	2004-12-09	DPP-IV-inhibitorer

Country Status (23)

Country	Link
US (1)	US20080027035A1 (da)
EP (2)	EP1541143A1 (da)
JP (1)	JP2007513910A (da)
KR (1)	KR100845397B1 (da)
CN (1)	CN1905868A (da)
AT (1)	ATE372767T1 (da)
AU (1)	AU2004296553B2 (da)
BR (1)	BRPI0417458A (da)
CA (1)	CA2548742A1 (da)
CY (1)	CY1106969T1 (da)
DE (1)	DE602004008895T2 (da)
DK (1)	DK1613304T3 (da)
ES (1)	ES2291966T3 (da)
HR (1)	HRP20070560T3 (da)
IL (1)	IL176062A0 (da)
MX (1)	MXPA06006652A (da)
NO (1)	NO20062644L (da)
PL (1)	PL1613304T3 (da)
PT (1)	PT1613304E (da)
RU (1)	RU2006119302A (da)
SI (1)	SI1613304T1 (da)
WO (1)	WO2005056003A1 (da)
ZA (1)	ZA200604719B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1990468A (zh)	2001-06-27	2007-07-04	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
EP1589969A4 (en)	2003-01-17	2008-08-13	Merck & Co Inc	3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
US7388019B2 (en)	2003-01-31	2008-06-17	Merck & Co., Inc.	3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE602004023932D1 (de)	2003-05-14	2009-12-17	Merck & Co Inc	3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
CA2526770A1 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2527806A1 (en)	2003-06-17	2004-12-29	Merck & Co., Inc.	Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004261186A1 (en)	2003-07-31	2005-02-10	Merck & Co., Inc.	Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1756074A4 (en)	2004-05-04	2010-05-19	Merck Sharp & Dohme	1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
US7671073B2 (en)	2004-05-18	2010-03-02	Merck Sharp & Dohme Corp.	Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006098342A1 (en) *	2005-03-16	2006-09-21	Astellas Pharma Inc.	Piperazinyl compounds
WO2007053819A2 (en)	2005-10-31	2007-05-10	Bristol-Myers Squibb Company	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
US20090156465A1 (en)	2005-12-30	2009-06-18	Sattigeri Jitendra A	Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
BRPI0709984A2 (pt)	2006-04-12	2011-08-02	Probiodrug Ag	inibidores de enzima
WO2008028662A1 (en) *	2006-09-07	2008-03-13	Santhera Pharmaceuticals (Schweiz) Ag	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
EP1905759A1 (en) *	2006-09-07	2008-04-02	Santhera Pharmaceuticals (Schweiz) AG	N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
DK2091948T3 (da)	2006-11-30	2012-07-23	Probiodrug Ag	Nye inhibitorer af glutaminylcyclase
KR20080071476A (ko) *	2007-01-30	2008-08-04	주식회사 엘지생명과학	신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
ES2533484T3 (es)	2007-04-18	2015-04-10	Probiodrug Ag	Derivados de tiourea como inhibidores de la glutaminil ciclasa
CN101663282B (zh) *	2007-04-19	2012-02-15	东亚制药株式会社	包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物
US7860904B2 (en) *	2007-04-24	2010-12-28	Microsoft Corporation	Standalone execution of incomplete data flows
WO2009003681A1 (en) *	2007-07-02	2009-01-08	Santhera Pharmaceuticals (Schweiz) Ag	Dpp-iv inhibitors
EP2019099A1 (en) *	2007-07-02	2009-01-28	Santhera Pharmaceuticals (Schweiz) AG	Dpp-IV inhibitors
CN102838589B (zh) *	2008-09-23	2014-03-26	成都地奥制药集团有限公司	经甲磺酰化的制备n取代的吡咯烷衍生物的方法
CN101823987B (zh) *	2009-03-06	2014-06-04	中国科学院上海药物研究所	一类新的dpp-ⅳ抑制剂及其制备方法和用途
UA107360C2 (en)	2009-08-05	2014-12-25	Biogen Idec Inc	Bicyclic aryl sphingosine 1-phosphate analogs
US8486940B2 (en)	2009-09-11	2013-07-16	Probiodrug Ag	Inhibitors
US9181233B2 (en)	2010-03-03	2015-11-10	Probiodrug Ag	Inhibitors of glutaminyl cyclase
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
DK2672823T3 (da)	2011-02-07	2016-11-28	Biogen Ma Inc	S1p-modulerende midler
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20160350201A1 (en) *	2015-05-27	2016-12-01	International Business Machines Corporation	Etl data flow design assistance through progressive context matching
CN108289867A (zh)	2015-07-02	2018-07-17	地平线孤儿病有限责任公司	Ado-抗性的半胱胺类似物和其用途
CN105362268A (zh) *	2015-12-15	2016-03-02	上海壹志医药科技有限公司	脱亚甲基小檗碱的药物用途
CN106526047A (zh) *	2016-11-15	2017-03-22	迪沙药业集团有限公司	R‑琥珀酸曲格列汀光学纯度的测定方法
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6573287B2 (en) *	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
ATE318139T1 (de) *	2001-06-20	2006-03-15	Merck & Co Inc	Dipeptidylpeptidase-hemmer zur behandlung von diabetes
EP1406872B1 (en) *	2001-06-20	2007-12-19	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
DE10340800A1 (de) *	2002-12-20	2004-07-01	Merck Patent Gmbh	Funktionalisierung unreaktiver Substrate

2003
- 2003-12-09 EP EP03028211A patent/EP1541143A1/en not_active Withdrawn
2004
- 2004-12-09 PL PL04803694T patent/PL1613304T3/pl unknown
- 2004-12-09 BR BRPI0417458-5A patent/BRPI0417458A/pt not_active IP Right Cessation
- 2004-12-09 ES ES04803694T patent/ES2291966T3/es not_active Expired - Lifetime
- 2004-12-09 PT PT04803694T patent/PT1613304E/pt unknown
- 2004-12-09 CA CA002548742A patent/CA2548742A1/en not_active Abandoned
- 2004-12-09 DK DK04803694T patent/DK1613304T3/da active
- 2004-12-09 MX MXPA06006652A patent/MXPA06006652A/es not_active Application Discontinuation
- 2004-12-09 EP EP04803694A patent/EP1613304B1/en not_active Expired - Lifetime
- 2004-12-09 RU RU2006119302/04A patent/RU2006119302A/ru not_active Application Discontinuation
- 2004-12-09 AU AU2004296553A patent/AU2004296553B2/en not_active Ceased
- 2004-12-09 AT AT04803694T patent/ATE372767T1/de not_active IP Right Cessation
- 2004-12-09 DE DE602004008895T patent/DE602004008895T2/de not_active Expired - Fee Related
- 2004-12-09 HR HR20070560T patent/HRP20070560T3/xx unknown
- 2004-12-09 JP JP2006543480A patent/JP2007513910A/ja not_active Withdrawn
- 2004-12-09 CN CNA2004800404476A patent/CN1905868A/zh active Pending
- 2004-12-09 US US10/582,054 patent/US20080027035A1/en not_active Abandoned
- 2004-12-09 SI SI200430469T patent/SI1613304T1/sl unknown
- 2004-12-09 KR KR1020067013752A patent/KR100845397B1/ko not_active Expired - Fee Related
- 2004-12-09 WO PCT/EP2004/014040 patent/WO2005056003A1/en active Application Filing
2006
- 2006-05-31 IL IL176062A patent/IL176062A0/en unknown
- 2006-06-08 NO NO20062644A patent/NO20062644L/no not_active Application Discontinuation
- 2006-06-08 ZA ZA200604719A patent/ZA200604719B/xx unknown
2007
- 2007-10-30 CY CY20071101404T patent/CY1106969T1/el unknown

Also Published As

Publication number	Publication date
DE602004008895T2 (de)	2008-06-19
PL1613304T3 (pl)	2008-02-29
MXPA06006652A (es)	2007-02-20
AU2004296553B2 (en)	2008-09-04
SI1613304T1 (sl)	2007-12-31
CY1106969T1 (el)	2012-09-26
HK1087022A1 (en)	2006-10-06
AU2004296553A1 (en)	2005-06-23
ZA200604719B (en)	2007-12-27
EP1541143A1 (en)	2005-06-15
KR20060108756A (ko)	2006-10-18
EP1613304A1 (en)	2006-01-11
NO20062644L (no)	2006-09-07
EP1613304B1 (en)	2007-09-12
JP2007513910A (ja)	2007-05-31
IL176062A0 (en)	2006-10-05
ATE372767T1 (de)	2007-09-15
CN1905868A (zh)	2007-01-31
DE602004008895D1 (en)	2007-10-25
WO2005056003A1 (en)	2005-06-23
KR100845397B1 (ko)	2008-07-09
PT1613304E (pt)	2007-11-14
RU2006119302A (ru)	2008-01-20
CA2548742A1 (en)	2005-06-23
HRP20070560T3 (hr)	2008-01-31
US20080027035A1 (en)	2008-01-31
ES2291966T3 (es)	2008-03-01
BRPI0417458A (pt)	2007-03-13

Publication	Publication Date	Title
NO20062644L (no)	2006-09-07	DPP-IV inhibitorer
ATE427932T1 (de)	2009-04-15	11beta-hsd1-inhibitoren
NO20070089L (no)	2007-01-05	DPP-IV inhibitorer
ZA200309887B (en)	2004-07-20	Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
MXPA03011039A (es)	2004-03-19	Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
EA200500017A1 (ru)	2005-06-30	Новые соединения
MX2007000505A (es)	2007-06-25	Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
EP1604989A8 (en)	2006-03-15	DPP-IV inhibitors
BR0314688A (pt)	2005-08-02	Novos derivados de piperidina para utilização no tratamento de estados de doença mediados pela quimiocina
NO20034291L (no)	2003-11-24	2-aminopropanolderivater
SE0102616D0 (sv)	2001-07-25	Novel compounds
DE50202504D1 (de)	2005-04-21	Neue 4-aminofuropyrimidine und ihre verwendung
CR9182A (es)	2007-08-28	Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
NO20043016L (no)	2004-07-15	6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
MXPA03009548A (es)	2004-05-24	Arilsulfonamidas como agentes antivirales.
MXPA04006266A (es)	2004-09-27	Pirimidotriazinas como inhibidores de fosfatasa.
NO20054787D0 (no)	2005-10-18	Indenderivater som farmasotiske midler
MX2008001778A (es)	2008-04-07	Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CY1107101T1 (el)	2012-10-24	Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
WO2003014094A3 (de)	2003-06-05	Heterocyclylarylsulfonamide
DK1648906T3 (da)	2008-02-04	Organo-silicium-forbindelser og deres anvendelse
ATE374751T1 (de)	2007-10-15	3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
MXPA04002640A (es)	2004-06-07	Esteres de analogos de 3-desoxi-vitamina d3.
ATE334977T1 (de)	2006-08-15	Discodermolid-analoga und ihre pharmazeutische verwendung
DE60202575D1 (de)	2005-02-17	3,4-Dihydro-1H-Naphthalin-Derivate als hoch selektive Cyclooxygenase-2-Inhibitoren